期刊文献+

低分子量肝素钙口服制剂的研究 被引量:2

Study on the oral preparation of low molecular weight heparin calcium
下载PDF
导出
摘要 目的研究低分子量肝素钙(LMWH-Ca)口服制剂的制备和口服吸收。方法将LMWH-Ca用聚乙二醇制成微囊、β-环糊精(-βCD)包合和在LMWH-Ca口服液中加入促胃肠道黏膜吸收剂N-[10-(2-羟基苯甲酰基)氨基]癸酸钠(SNAD)等方法制备成不同制剂后,SD大鼠采用灌胃给药,用生色底物法测定不同取样时间的药物浓度。结果在试验的LMWH-Ca口服处方中,加入SNAD的处方具有较好的吸收。结论SNAD对LMWH-Ca口服制剂具有优良的促胃肠道黏膜吸收能力,有助于LMWH-Ca口服制剂的深入研究。 Purpose To investigate the oral preparations of low molecular weight heparin calcium(LMWH-Ca) and the absorption of LMWH-Ca in the preparations administered orally. Methods LMWH-Ca preparations were prepared by microeneapsulation with PEG6000, inclusion with β-CD or adding sodium N-[10-(2-hydrox- ybenzoyl)amino]decanoate (SNAD)to enhance the absorption of LMWH-Ca from the gastrointestinal tract, and the concentrations of LMWH-Ca in plasma at varied time after giving the LMWH-Ca preparations to rats intragastrically were determined by chromogenic substrate method. Results Among the preparations of LMWH-Ca, the one containing SNAD had better absorption. Conclusion SNAD has good ability to enhance absorption of oral LMWH-Ca from the gastrointestinal tract. It would be good to have further study on LMWH-Ca oral prepa- rations.
出处 《中国生化药物杂志》 CAS CSCD 2008年第6期403-405,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 低分子量肝素钙 口服制剂 生色底物法 SNAD low molecular weight heparin calcium oral preparation chromogenic substrate method sodium N-[10-(2-hydroxybenzoyl) amino ] decanoate
  • 相关文献

参考文献15

  • 1李京,范慧红,徐康森.低分子肝素药用现状及质量标准概况[J].中国生化药物杂志,2004,25(1):53-55. 被引量:31
  • 2Prasad Y V, Minamimoto T, Yoshikawa Y, et al. In situ intestinal absorption studies on low molecular weight heparin in rats using Labrasol as absorption enhancer[ J]. Int J Pharm, 2004,271 (1-2) : 225-232.
  • 3Ito Y, Kusawake T, Prasad Y V, et al. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies[J]. Int J Pharm,2006,317(2) : 114-119.
  • 4Khashayar S, Mark D G, Andrea L B, et al. Oral low molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat [J] .J Vasc Surg,1999,30(3):526-532.
  • 5谢继青,梁爱君,于燕莉,袁成.生色底物法测定低分子肝素钠注射液效价[J].解放军药学学报,2003,19(3):221-223. 被引量:4
  • 6李湛君,徐康森.用分光光度法测定低分子肝素的效价[J].药物分析杂志,1999,19(2):133-136. 被引量:7
  • 7British Pharmacopoeia [ S]. Volume Ⅰ. 1998 : 667-670.
  • 8夏红梅,徐银祥,李兆羿,胡容峰.低分子量肝素钙效价测定方法的改进[J].安徽医药,2004,8(2):93-94. 被引量:1
  • 9Lee Y K, Kim S K, Lee D Y, ct al. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys [ J ]. J Controlled Release, 2006,111 (3) : 290-298.
  • 10Kim S K, Lee E H, Vaishali B, et al. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates [ J ]. J Controlled Release, 2005,105 ( 1-2 ) : 32-42.

二级参考文献17

  • 1T.W.Barrowcliffe,冯仁田.低分子肝素的一种国际标准[J].中国生化药物杂志,1993,14(3):74-78. 被引量:2
  • 2张利伟,王鸿利.低分子量肝素的研究进展[J].国外医学(输血及血液学分册),1995,18(6):343-346. 被引量:34
  • 3姬胜利,张天民.肝素与低分子肝素的研究进展[J].中国生化药物杂志,1996,17(5):216-219. 被引量:33
  • 4张天民 王凤山 等.肝素的生色底物测定.生物药物研究[M].北京:人民卫生出版社,1997.148.
  • 5周海钧 申蕴如.生物检定统计方法[M].北京:人民卫生出版社,1988..
  • 6.WS-541(X-428)-98(2).中华人民共和国国家药品监督管理局试行标准[S].,1998..
  • 7国家药典委员会.中国药典(二部)临床用药须知:2000年版[M].北京:化学工业出版社,2001.411.
  • 8.英国药典[S].2002年版[M].,2002.443,731,560,1024,1125,1505.
  • 9Handeland GF. Assay of unfractionated and LMW heparia with chromogenic substrates: Twin methods with factor X a and thrombin[J].Thromb Res , 1984,35:627.
  • 10Walenga JM. Amidolitic antifactor X a assay in the Jaboratory evaluation of heparin and low molecular weight fractions[J]. Semin Thromb Hernost , 1984,112:100.

共引文献39

同被引文献32

  • 1谢继青,牛爱军,方喜峰,程霞,张妍,喻学红.低分子肝素舌下含片处方筛选及其药效观察[J].中国医院药学杂志,2004,24(10):590-592. 被引量:5
  • 2崔慧斐,张天民.低抗凝肝素来源低分子肝素口服制剂的研究[J].中国生化药物杂志,1993,14(4):10-15. 被引量:14
  • 3汪龙,邓瑾,金玉燕,张钧寿.低分子肝素微乳及其纳米脂质体作大鼠口服抗凝效果的比较[J].江苏药学与临床研究,2005,13(2):4-6. 被引量:9
  • 4陈公英,李敏伟,陈智,顾新宇,周慧明.低分子肝素抗肝癌细胞增殖及机制研究[J].中国肿瘤,2006,15(5):343-345. 被引量:11
  • 5LAMPRECHT A, UBRICH N, MAINCENT P. Oral low molecular weight heparin delivery by microparticles from complex coacervation [J]. Eur J Pharm Biopharm, 2007, 67(3): 632-638.
  • 6ANURSSON P, LINDMARK T, DAVIS S S, et al. Effect of chitosan on the permeability of intestinal epuholial cells(Caco-2) [J]. Pharm Res, 1994, 11(9): 1358-1361.
  • 7ANDERSSON M, LOFROTH J E. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable mieroemulsion [J]. Int J Pharm, 2003, 257(1-2): 305-309.
  • 8HOFFART V, UBRICH N, LAMPRECHT A, et al. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers [J]. Drug Deliv, 2003, 10(1): 1-7.
  • 9HOFFART V, UBRICH N, SIMONIN C, et al. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics [J]. Drug Dev Ind Pharm, 2002, 28(9): 1091-1099.
  • 10SALARTASH K, MARK D, GONZE M D, et al. Oral low molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat [C]. Presented at the Twenty-third Annual Meeting of the Southern Associationfor Vascular Surgery, Naples, Fla, 1999: 27-30.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部